Therapeutic Effect of Costunolide in Autoimmune Hepatitis: Network Pharmacology and Experimental Validation

Novel treatments for autoimmune hepatitis (AIH) are highly demanded due to the limitations of existing therapeutic agents. Costunolide is a promising candidate due to its anti-inflammatory and hepatoprotective function, but its effect in AIH remains obscure. In this study, we integrated network phar...

Full description

Bibliographic Details
Main Authors: Zheng Huang, Shangshu Nie, Shuhui Wang, Han Wang, Jin Gong, Wei Yan, Dean Tian, Mei Liu
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Pharmaceuticals
Subjects:
Online Access:https://www.mdpi.com/1424-8247/16/2/316
_version_ 1797618777580371968
author Zheng Huang
Shangshu Nie
Shuhui Wang
Han Wang
Jin Gong
Wei Yan
Dean Tian
Mei Liu
author_facet Zheng Huang
Shangshu Nie
Shuhui Wang
Han Wang
Jin Gong
Wei Yan
Dean Tian
Mei Liu
author_sort Zheng Huang
collection DOAJ
description Novel treatments for autoimmune hepatitis (AIH) are highly demanded due to the limitations of existing therapeutic agents. Costunolide is a promising candidate due to its anti-inflammatory and hepatoprotective function, but its effect in AIH remains obscure. In this study, we integrated network pharmacology and experimental validation to reveal the effect and mechanism of costunolide in AIH. A total of 73 common targets of costunolide and AIH were obtained from databases. Pathway enrichment analysis indicated that PI3K-AKT pathway was the core pathway of costunolide in AIH. Protein–protein interaction network analysis and molecular docking revealed that SRC and IGF1R might play critical roles. In two murine AIH models, costunolide significantly attenuated liver injury, inflammation, and fibrosis reflected by the liver gross appearance, serum transaminases, necrosis area, spleen index, immune cell infiltration, and collagen deposition. Western blot and immunohistochemistry confirmed that phosphorylated AKT, SRC, and IGF1R were upregulated in AIH models, and costunolide administration could inhibit the phosphorylation of these proteins. In summary, costunolide significantly ameliorates murine AIH. The therapeutic effect might work by suppressing the activation of PI3K-AKT pathway and inhibiting the phosphorylation of SRC and IGF1R. Our research reveals the potent therapeutic effect of costunolide in AIH and the potential role of SRC and IGF1R in AIH for the first time, which may further contribute to the novel drug development for AIH and other autoimmune diseases.
first_indexed 2024-03-11T08:18:23Z
format Article
id doaj.art-dc64f47c66b841119dcaaab64952b38c
institution Directory Open Access Journal
issn 1424-8247
language English
last_indexed 2024-03-11T08:18:23Z
publishDate 2023-02-01
publisher MDPI AG
record_format Article
series Pharmaceuticals
spelling doaj.art-dc64f47c66b841119dcaaab64952b38c2023-11-16T22:37:57ZengMDPI AGPharmaceuticals1424-82472023-02-0116231610.3390/ph16020316Therapeutic Effect of Costunolide in Autoimmune Hepatitis: Network Pharmacology and Experimental ValidationZheng Huang0Shangshu Nie1Shuhui Wang2Han Wang3Jin Gong4Wei Yan5Dean Tian6Mei Liu7Department of Gastroenterology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, ChinaDepartment of Gastroenterology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, ChinaDepartment of Gastroenterology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, ChinaDepartment of Gastroenterology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, ChinaDepartment of Gastroenterology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, ChinaDepartment of Gastroenterology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, ChinaDepartment of Gastroenterology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, ChinaDepartment of Gastroenterology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, ChinaNovel treatments for autoimmune hepatitis (AIH) are highly demanded due to the limitations of existing therapeutic agents. Costunolide is a promising candidate due to its anti-inflammatory and hepatoprotective function, but its effect in AIH remains obscure. In this study, we integrated network pharmacology and experimental validation to reveal the effect and mechanism of costunolide in AIH. A total of 73 common targets of costunolide and AIH were obtained from databases. Pathway enrichment analysis indicated that PI3K-AKT pathway was the core pathway of costunolide in AIH. Protein–protein interaction network analysis and molecular docking revealed that SRC and IGF1R might play critical roles. In two murine AIH models, costunolide significantly attenuated liver injury, inflammation, and fibrosis reflected by the liver gross appearance, serum transaminases, necrosis area, spleen index, immune cell infiltration, and collagen deposition. Western blot and immunohistochemistry confirmed that phosphorylated AKT, SRC, and IGF1R were upregulated in AIH models, and costunolide administration could inhibit the phosphorylation of these proteins. In summary, costunolide significantly ameliorates murine AIH. The therapeutic effect might work by suppressing the activation of PI3K-AKT pathway and inhibiting the phosphorylation of SRC and IGF1R. Our research reveals the potent therapeutic effect of costunolide in AIH and the potential role of SRC and IGF1R in AIH for the first time, which may further contribute to the novel drug development for AIH and other autoimmune diseases.https://www.mdpi.com/1424-8247/16/2/316costunolideautoimmune hepatitisnetwork pharmacologyimmune-mediated liver injuryPI3K-AKTSRC
spellingShingle Zheng Huang
Shangshu Nie
Shuhui Wang
Han Wang
Jin Gong
Wei Yan
Dean Tian
Mei Liu
Therapeutic Effect of Costunolide in Autoimmune Hepatitis: Network Pharmacology and Experimental Validation
Pharmaceuticals
costunolide
autoimmune hepatitis
network pharmacology
immune-mediated liver injury
PI3K-AKT
SRC
title Therapeutic Effect of Costunolide in Autoimmune Hepatitis: Network Pharmacology and Experimental Validation
title_full Therapeutic Effect of Costunolide in Autoimmune Hepatitis: Network Pharmacology and Experimental Validation
title_fullStr Therapeutic Effect of Costunolide in Autoimmune Hepatitis: Network Pharmacology and Experimental Validation
title_full_unstemmed Therapeutic Effect of Costunolide in Autoimmune Hepatitis: Network Pharmacology and Experimental Validation
title_short Therapeutic Effect of Costunolide in Autoimmune Hepatitis: Network Pharmacology and Experimental Validation
title_sort therapeutic effect of costunolide in autoimmune hepatitis network pharmacology and experimental validation
topic costunolide
autoimmune hepatitis
network pharmacology
immune-mediated liver injury
PI3K-AKT
SRC
url https://www.mdpi.com/1424-8247/16/2/316
work_keys_str_mv AT zhenghuang therapeuticeffectofcostunolideinautoimmunehepatitisnetworkpharmacologyandexperimentalvalidation
AT shangshunie therapeuticeffectofcostunolideinautoimmunehepatitisnetworkpharmacologyandexperimentalvalidation
AT shuhuiwang therapeuticeffectofcostunolideinautoimmunehepatitisnetworkpharmacologyandexperimentalvalidation
AT hanwang therapeuticeffectofcostunolideinautoimmunehepatitisnetworkpharmacologyandexperimentalvalidation
AT jingong therapeuticeffectofcostunolideinautoimmunehepatitisnetworkpharmacologyandexperimentalvalidation
AT weiyan therapeuticeffectofcostunolideinautoimmunehepatitisnetworkpharmacologyandexperimentalvalidation
AT deantian therapeuticeffectofcostunolideinautoimmunehepatitisnetworkpharmacologyandexperimentalvalidation
AT meiliu therapeuticeffectofcostunolideinautoimmunehepatitisnetworkpharmacologyandexperimentalvalidation